In addition, activation of ERK1/2 by PGE2 was strongly suppressed by EP4 antagonist ONO-208 compound, indicating that ERK1/2 signaling cascade was involved in PGE2-EP4-mediated cardiac hypertrophy [57, 68]. Here, MAPK3 is linked to cardiac hypertrophy.